Acadia will have world exclusivity on Rett for several years given that after this failed study the others are light years behind, Daybue will be able to reach peak sales without competition, Acadia must hurry after Canada to present MAA in Europe where patients are certainly praying to have the drug as soon as possible, we have no rivals!!! INCREDIBLE!!!
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-92
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.35 |
Change
0.070(0.57%) |
Mkt cap ! $1.578B | |||
| Open | High | Low | Value | Volume |
| $12.25 | $12.45 | $12.02 | $7.808M | 638.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41 | $12.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.37 | 1579 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |